PR Newswire/Les Echos/
NYSE Euronext Welcomes AbbVie to Its European and U.S. Markets
Global biopharmaceutical company cross-lists and rings the Opening Bell SM in
NEW YORK and PARIS, Jan. 2, 2013 -- Today, AbbVie (NYSE: ABBV), a global
research-based biopharmaceutical company formed in 2013 following separation
from Abbott (NYSE: ABT), marked its cross-listing on NYSE Euronext (NYX)
markets in Europe and the United States by ringing the Opening Bell in
New York. AbbVie used the streamlined, cost-effective Fast Path process to
cross-list in Europe, making it the fifteenth company to take advantage of
this procedure since it was made available by NYSE Euronext in 2008.
AbbVie's Common Stock was admitted to listing and trading on the NYSE Euronext
markets by direct listing of its approximately 1.58 billion existing shares
making up its capital and representing a market capitalization of 40 billion/
Richard Gonzalez, CEO of AbbVie, said: "Today AbbVie launches with an
outstanding portfolio, a solid pipeline and enthusiastic people who will serve
patients and deliver growth. With those assets and a relentless focus on
innovation we intend to create significant value for our shareholders."
"We welcome AbbVie to the community of NYSE Euronext listed companies and
applaud its decision to cross-list on our European and U.S. markets which will
rein force its global identity", added Scott Cutler, EVP, Head of Global
Listings at NYSE Euronext. "This is the beginning of a lasting relationship
that will give AbbVie the benefits of the highest levels of service, liquidity
and transparency available through NYSE Euronext."
Notes to Editors:
1 Background about cross-listing on NYSE Euronext European markets
* NYSE Euronext is the first and only exchange group to offer a truly global
cross-market listing, trading and visibility platform, providing
cost-effective, convenient access to investors and business partners in
the US and in Europe.
* NYSE Euronext is the first exchange group to offer companies the ability
to trade and raise capital in and $ and reach investors and constituents
directly across continents and multiple time zones, regions and countries.
* Valuable for any company looking to enhance its global profile, support
an international business or expand its non-US investor base, a Fast Path
listing provides an easy, cost-effective way to gain a European trading
presence. Euronext regulators accept documentation, previously filed with
the SEC, to satisfy the EU Prospectus Directive. With Fast Path, a company
avoids the need to draft and translate a separate prospectus in order to
be admitted to trading. Documents filed with the SEC serve as the primary
component to obtain approval from the competent Euronext regulator. The
SEC documentation is combined with a summary "wrapper", addressing any
additional European and local requirements, forming the company's
2 Executives from AbbVie rang the Opening Bell at the New York Stock Exchange
on Wednesday, January 2, 2013.
Adelle Infante: 847-938-8745
Caroline Tourrier: +33 (0)1 49 27 10 82
AbbVie (NYSE: ABBV) is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott. AbbVie combines the focus and
passion of a leading-edge biotech with the expertise and structure of a
long-established pharmaceutical leader. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to develop and
market advanced therapies that address some of the world's most complex and
serious diseases. AbbVie aims to help patients live healthier lives and
collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ
approximately 21,000 people worldwide and market medicines in more than 170
countries. For further information on the company and its people, portfolio
and commitments, please visit http://www.abbvie.com/. Follow @abbvie on
Twitter or view careers on our Facebook or LinkedIn page.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and
provider of innovative trading technologies. The company's exchanges in Europe
and the United States trade equities, futures, options, fixed-income and
exchange-traded products. With approximately 8,000 listed issues (excluding
European Structured Products), NYSE Euronext's equities markets - the New York
Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca -
represent one-third of the world's equities trading, the most liquidity of any
global exchange group. NYSE Euronext also operates NYSE Liffe, one of the
leading European derivatives businesses and the world's second-largest
derivatives business by value of trading. The company offers a comprehensive
commercial technology, connectivity and market data products and services
through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more
information, please visit: http://www.nyx.com/.
CONTACT - Media: CONTACT - Investor Relations: nyx.com
Amsterdam +31.20.550.4488 Brussels +32.2.509.1392 New York +1.212.656.5700
Lisbon +351.217.900.029 London +44.20.7379.2789
New York +1.212.656.2411 Paris +22.214.171.124.11.33
Please follow us at:
SOURCE AbbVie Inc.
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
-0- Jan/03/2013 08:25 GMT
Press spacebar to pause and continue. Press esc to stop.